New delivery mechanisms, such as microneedle patches, sustained release implants, and targeted liposomal carriers, are being developed to enhance tissue targeting and minimize dosing frequency
Phase (approx.) Cagrilintide dose Frequency Weeks 14 0.25 mg Once weekly Weeks 58 0.5 mg Once weekly Weeks 912 1.0 mg Once weekly Weeks 1316 1.7 mg Once weekly Week 17 onward 2.4 mg (max studied) Once weekly This step-wise schedule mirrors the titration used in cagrilintide and CagriSema studies ( Lau et al., Lancet 2021
Research-grade cagrilintide from peptide suppliers varies significantly by vendor and may not match the pharmaceutical-grade material used in clinical trials
H 2 O 2 signaling leads to the release of Nrf2 from complexes with Kelch-like ECH-associated protein 1 (Keap1) and ubiquitin ligase Cullin 3 and into the nucleus, where it binds to antioxidant response elements (ARE) and activates the expression of its target gene GPX8, which in turn regulates the expression of ER calcium by regulating SERCA ( 2 O 2 signaling and inhibiting Nrf2 translocation to the nucleus, resulting in a decrease in GPX8, resulting in increased ER calcium content and signaling ( via GPX8, in the same study, after silencing Nrf2 in HeLa cells, GPX8 mRNA and protein levels also decreased, resulting in elevated ER and cytosolic calcium levels at rest and increased histamine-induced ER calcium release (Tokuda et al., 2019)
TB-500 Thymosin Beta-500, a synthetic version of naturally occurring Thymosin Beta-4